Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, through its subsidiaries, develops gene therapy products to treat patients with eye diseases. It focuses on developing a pipeline of recombinant adeno-associated virus vector-based gene therapy candidates targeting genetic variants in the complement pathway for age-related macular degeneration. The company is developing GT005, which is in Phase II clinical trials for the treatment of geographic atrophy secondary to age-related macular degeneration; and GT011, a preclinical recombinant adeno-associated virus gene therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom.

VISN

NASDAQ:VISN

Gyroscope Therapeutics Holdings plc